$GILD After carefully reading the report, I am openning a massive short position on $GILD during premarket hours. The drug increases mortality in cohort 4, does nothing to the other cohorts, and only enhance by little (perhaps statistical variance) to cohort 5... This thing is not going to be approved and prescribed by doctors worldwide (in Europe and Asia the mortality increase is a big NO-NO)... and that means losing 70-80% of the potential market...
  • 1
  • 1
1 Like